Modulight Receives Medical Laser Contract
TAMPERE, Finland, April 18, 2012 — Laser manufacturer Modulight Inc. announced that it designed, integrated and CE-certified an OEM medical laser system for PCI Biotech of Oslo, Norway, for a novel cancer therapy process.
Under a multiyear OEM manufacturing agreement, Modulight will deliver a CE-certified, seven-channel medical laser system solution to PCI Biotech for its PCI (PhotoChemical Internalisation) patented photochemical drug delivery technology used for cancer therapy and other diseases.
PCI is a technology for light-directed drug delivery by triggered endosomal release and was developed to introduce therapeutic molecules in a biologically active form specifically into diseased cells. The proprietary technology can provide local enhancement of a range of drugs, including several cancer drugs currently in clinical use.
“An essential part of our treatment process is the single-wavelength laser source that is used to activate the PCI process,” said Per Walday, CEO of PCI Biotech. “The wavelength and the dose of the laser light in the treated tissue must be carefully controlled, requiring excellence in designing and building a stable laser system at our desired wavelength.”
For more information, visit: www.modulight.com